AltraTech
Private Company
Total funding raised: $3.8M
Overview
AltraTech is pioneering a next-generation diagnostic platform designed to integrate serological and molecular testing into a single, rapid point-of-care device. The company's mission is to transform diagnostic workflows by providing comprehensive, multi-parameter results from a single sample, addressing needs in clinical triage, drug development, and personal health monitoring. Based in Cork, Ireland, AltraTech is developing a versatile technology with applications across infectious disease, chronic condition management, and pharmaceutical R&D.
Technology Platform
A multianalyte point-of-care diagnostic platform that uniquely integrates serology (antibody/antigen) and viral nucleic acid testing in a single device from one patient sample.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
AltraTech faces competition from leaders in molecular POC testing (e.g., Cepheid, BioFire) and rapid serology (e.g., Abbott, QuidelOrtho). Its main differentiation is the proposed native integration of both test types in a single device, aiming to provide a more comprehensive diagnostic result than current standalone solutions.